52 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
22 Not yet recruiting Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease
Conditions: HIV;   Smoking;   COPD
Intervention:
23 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
24 Active, not recruiting Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Condition: Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Ipilimumab
25 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Condition: Cancer, Solid Tumor
Interventions: Drug: Pembrolizumab 1 mg/kg;   Drug: Pembrolizumab 3 mg/kg;   Drug: Pembrolizumab 10 mg/kg;   Drug: Pembrolizumab MEL;   Drug: Pembrolizumab NSCLC;   Drug: Pembrolizumab MEL Low Dose;   Drug: Pembrolizumab MEL High Dose;   Drug: Pembrolizumab NSCLC Low Dose;   Drug: Pembrolizumab NSCLC High Dose;   Drug: Pembrolizumab NSCLC Medium Dose
26 Recruiting Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Gemcitabine
27 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
28 Active, not recruiting Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)
Condition: Malignant Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Dacarbazine;   Drug: Temozolomide
29 Recruiting Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: Cytology specimen;   Other: Laboratory biomarker analysis
30 Active, not recruiting ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan
Condition: Malignant Solid Tumor
Intervention: Biological: ONO-4538
31 Completed A Study of MDX-1106 to Treat Patients With Hepatitis C Infection
Condition: Hepatitis C
Interventions: Drug: MDX1106-02;   Drug: Placebo
32 Recruiting Safety Study of Nivolumab and Ipilimumab in Hematologic Malignancy
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
33 Recruiting Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.
Condition: Non-Small Lung Cancer, Epigenetic Therapy
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Drug: CC-486
34 Recruiting BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Conditions: Diffuse Large B-cell Lymphoma;   Hodgkin Lymphoma;   Metastatic Breast Cancer.;   Non-small Cell Lung Cancer
Intervention:
35 Recruiting Modulation of Immune Activation by Aspirin
Condition: HIV-1 Infection
Interventions: Drug: Aspirin;   Drug: Aspirin placebo
36 Not yet recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: nivolumab;   Biological: ipilimumab;   Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
37 Completed Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer
Condition: Cancer
Intervention: Drug: AMP-224
38 Recruiting A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Intervention: Drug: MPDL3280A
39 Recruiting A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Condition: Malignant Melanoma
Interventions: Drug: MPDL3280A;   Drug: Vemurafenib (Zelboraf®)
40 Recruiting A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Condition: Carcinoma, Transitional Cell , Bladder Cancer, Bladder Tumors, Urinary Bladder Neoplasms
Intervention: Drug: MPDL3280A

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-52) Show next page of results
Indicates status has not been verified in more than two years